Hutchison China MediTech (Chi-Med) has commenced a Phase I/II clinical trial of HMPL-453 in China for the treatment of solid tumours in patients carrying fibroblast growth factor receptor (FGFR) genetic alteration.

HMPL-453 is a highly selective and potent small-molecule inhibitor of fibroblast growth factor receptors (FGFR) one, two and three.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Designed to complement an ongoing Phase I trial in Australia, the multi-centre, single-arm, open-label, two-part Phase I/II trial will investigate the safety, tolerability, preliminary efficacy and pharmacokinetics (PK) of HMPL-453 as a monotherapy.

The initial dose-escalation part of the trial will include locally advanced or metastatic solid tumour patients for whom, irrespective of their genetic status, standard therapy does not exist or was ineffective or intolerable

"HMPL-453 is a highly selective and potent small-molecule inhibitor of fibroblast growth factor receptors (FGFR) one, two and three."

The first part will establish the maximum tolerated dose (MTD) and recommended dose for Phase II.

See Also:

The second dose-expansion part will assess the safety, tolerability, preliminary anti-tumour efficacy and PK at the recommended Phase II dose.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Patients with FGFR dysregulated tumours and other solid tumours such as advanced bladder cancer and advanced cholangiocarcinoma will be included in the second part.

The primary endpoint of the dose-expansion part is objective response rate (ORR), while secondary endpoints include safety, duration of response (DoR), progression-free survival (PFS), disease control rate (DCR) and overall survival (OS).

According to the data from pre-clinical studies, HMPL-453 indicated superior potency, better kinase selectivity and a favourable safety profile, when compared to other drugs belonging to the same class.